Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170


Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis.

Landre T, Des Guetz G, Vergnenegre A, Chouaid C.

Ann Oncol. 2019 Apr;30 Suppl 2:ii60. doi: 10.1093/annonc/mdz063.063. No abstract available.


Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01).

Vergnenègre A, Basse V, Le Garff G, Bylicki O, Dubos-Arvis C, Comet B, Marcq M, Le Treut J, Auliac JB, Madroszyk A, Fraboulet G, Crequit J, Thomas P, Paleiron N, Monnet I; French Lung Cancer Group.

Cancer Manag Res. 2019 Dec 27;11:10821-10826. doi: 10.2147/CMAR.S219984. eCollection 2019.


Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC 04-2017).

Vergnenegre A, Monnet I, Bizieux A, Bernardi M, Chiapa AM, Léna H, Chouaïd C, Robinet G.

Future Oncol. 2020 Feb;16(4):5-10. doi: 10.2217/fon-2019-0730. Epub 2020 Jan 2.


Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).

Vergnenegre A, Geier M, Guisier F, Lamy R, Comet B, Le Garff G, Do P, Janicot H, Morel H, Decroisette C, Andre M, Falchero L, Paleiron N, Monnet I; GFPC Team.

Cancer Med. 2020 Jan;9(2):432-439. doi: 10.1002/cam4.2716. Epub 2019 Nov 20.


First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.

Landre T, Des Guetz G, Chouahnia K, Taleb C, Vergnenègre A, Chouaïd C.

J Cancer Res Clin Oncol. 2020 Feb;146(2):441-448. doi: 10.1007/s00432-019-03070-3. Epub 2019 Nov 4.


Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS.

N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.


Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers.

Dusselier M, Deluche E, Delacourt N, Ballouhey J, Egenod T, Melloni B, Vergnenègre C, Veillon R, Vergnenègre A.

PLoS One. 2019 Jul 17;14(7):e0219060. doi: 10.1371/journal.pone.0219060. eCollection 2019.


Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer.

Auliac JB, Saboundji K, Andre M, Madelaine J, Quere G, Masson P, Vergnenegre A, Lamy R, Raymond S, Chiappa AM, Hauss PA, Fournel P, Corre R, Chouaid C.

Target Oncol. 2019 Jun;14(3):307-314. doi: 10.1007/s11523-019-00646-4.


Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.

Karachaliou N, Bracht JWP, Fernandez Bruno M, Drozdowskyj A, Gimenez Capitan A, Moran T, Carcereny E, Cobo M, Domine M, Chaib I, Ramirez JL, Camps C, Provencio M, Vergnenegre A, Lopez-Vivanco G, Majem M, Massuti B, Rosell R.

J Thorac Oncol. 2019 Feb;14(2):304-310. doi: 10.1016/j.jtho.2018.10.168. Epub 2018 Nov 22.


Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14.

Auliac JB, Bayle S, Vergnenegre A, Le Caer H, Falchero L, Gervais R, Doubre H, Vinas F, Marin B, Chouaid C.

Curr Oncol. 2018 Oct;25(5):e398-e402. doi: 10.3747/co.25.3945. Epub 2018 Oct 31.


Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review.

Lesueur P, Martel-Laffay I, Escande A, Kissel M, Locher C, Gervais R, Schott R, Vergnenegre A, Chouaid C.

Expert Rev Anticancer Ther. 2018 Nov;18(11):1159-1165. doi: 10.1080/14737140.2018.1518714. Epub 2018 Sep 17.


Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC).

Vergnenègre A, Chouaïd C.

Expert Rev Pharmacoecon Outcomes Res. 2018 Oct;18(5):519-528. doi: 10.1080/14737167.2018.1485099. Epub 2018 Jun 14. Review.


Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06).

Locher C, Pourel N, Le Caer H, Berard H, Auliac JB, Monnet I, Descourt R, Vergnenègre A, Lafay IM, Greillier L, Chouaïd C.

Lung Cancer. 2018 Jul;121:25-29. doi: 10.1016/j.lungcan.2018.04.017. Epub 2018 Apr 22.


Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazieres J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenegre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B.

ERJ Open Res. 2018 Feb 13;4(1). pii: 00058-2017. doi: 10.1183/23120541.00058-2017. eCollection 2018 Jan.


Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group.

Le Caer H, Borget I, Corre R, Locher C, Raynaud C, Decroisette C, Berard H, Audigier-Valette C, Dujon C, Auliac JB, Crequit J, Monnet I, Vergnenegre A, Chouaid C.

J Thorac Dis. 2017 Oct;9(10):3747-3754. doi: 10.21037/jtd.2017.09.51.


Second-line treatments of small-cell lung cancers.

Baize N, Monnet I, Greillier L, Quere G, Kerjouan M, Janicot H, Vergnenegre A, Auliac JB, Chouaid C.

Expert Rev Anticancer Ther. 2017 Nov;17(11):1033-1043. doi: 10.1080/14737140.2017.1372198. Epub 2017 Sep 8. Review.


Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).

Auliac JB, Monnet I, Dubos-Arvis C, Chiappa AM, Baize N, Bota S, Vergnenegre A, Doubre H, Locher C, Bizieux A, Robinet G, Chouaid C.

Target Oncol. 2017 Dec;12(6):833-838. doi: 10.1007/s11523-017-0520-7.


Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.

Chouaid C, Luciani L, LeLay K, Do P, Bennouna J, Perol M, Moro-Sibilot D, Vergnenègre A, de Pouvourville G.

J Thorac Oncol. 2017 Oct;12(10):1496-1502. doi: 10.1016/j.jtho.2017.07.013. Epub 2017 Jul 24.


Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.

Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenegre A, Robinet G, Auliac JB, Gervais R, Chouaid C.

Target Oncol. 2017 Oct;12(5):563-569. doi: 10.1007/s11523-017-0510-9. Review.


Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.

Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, de Marinis F, Passaro A, Carcereny E, Reguart N, Campelo CG, Teixido C, Sperduti I, Rodriguez S, Lazzari C, Verlicchi A, de Aguirre I, Queralt C, Wei J, Estrada R, Puig de la Bellacasa R, Ramirez JL, Jacobson K, Ditzel HJ, Santarpia M, Viteri S, Molina MA, Zhou C, Cao P, Ma PC, Bivona TG, Rosell R.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx014.


Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home.

Touati M, Lamarsalle L, Moreau S, Vergnenègre F, Lefort S, Brillat C, Jeannet L, Lagarde A, Daulange A, Jaccard A, Vergnenègre A, Bordessoule D.

Support Care Cancer. 2016 Dec;24(12):5007-5014. Epub 2016 Aug 15.


Reply to R.D. Nipp et al, M.-J. Molina-Garrido et al, and A. Gajra et al.

Corre R, Léna H, Vergnenègre A, Chouaïd C.

J Clin Oncol. 2016 Nov 20;34(33):4050-4051. doi: 10.1200/JCO.2016.69.1105. Epub 2016 Oct 31. No abstract available.


Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.

Monnet I, Audigier-Valette C, Girard N, Vergnenègre A, Molinier O, Souquet PJ, Blanchon F, Bonnetain F, Taguieva-Pioger N, Lamour C, Wislez M.

Lung Cancer. 2016 Aug;98:84-90. doi: 10.1016/j.lungcan.2016.05.016. Epub 2016 May 26.


Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.

Bonanno L, Costa C, Majem M, Sanchez JJ, Rodriguez I, Gimenez-Capitan A, Molina-Vila MA, Vergnenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R.

BMC Cancer. 2016 May 14;16:312. doi: 10.1186/s12885-016-2339-5.


Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.

Deplanque G, Gervais R, Vergnenegre A, Falchero L, Souquet PJ, Chavaillon JM, Taviot B, Fraboulet G, Saal H, Robert C, Chosidow O; CYTAR investigators.

J Am Acad Dermatol. 2016 Jun;74(6):1077-85. doi: 10.1016/j.jaad.2016.01.019. Epub 2016 Mar 4.


Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.

Vergnenegre A, Massuti B, de Marinis F, Carcereny E, Felip E, Do P, Sanchez JM, Paz-Arez L, Chouaid C, Rosell R; Spanish Lung Cancer Group, Italian Association of Thoracic Oncology, and French Lung Cancer Group.

J Thorac Oncol. 2016 Jun;11(6):801-7. doi: 10.1016/j.jtho.2016.02.004. Epub 2016 Feb 18.


Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.

Corre R, Greillier L, Le Caër H, Audigier-Valette C, Baize N, Bérard H, Falchero L, Monnet I, Dansin E, Vergnenègre A, Marcq M, Decroisette C, Auliac JB, Bota S, Lamy R, Massuti B, Dujon C, Pérol M, Daurès JP, Descourt R, Léna H, Plassot C, Chouaïd C.

J Clin Oncol. 2016 May 1;34(13):1476-83. doi: 10.1200/JCO.2015.63.5839. Epub 2016 Feb 16.


Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.

Fournel P, Vergnenégre A, Robinet G, Léna H, Gervais R, Le Caer H, Souquet PJ, Chavaillon JM, Bozonnat MC, Daurès JP, Chouaid C, Martel-Lafay I; GFPC and IFCT Team.

Eur J Cancer. 2016 Jan;52:181-7. doi: 10.1016/j.ejca.2015.10.072. Epub 2015 Dec 12.


BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.

Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R.

Sci Rep. 2015 Dec 7;5:17499. doi: 10.1038/srep17499.


Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).

Raynaud C, Greillier L, Mazieres J, Monnet I, Mastroianni B, Robinet G, Fraboulet G, Dixmier A, Berard H, Lamy R, Letreut J, Lena H, Oliviero G, Botta S, Vergnenegre A, Borget I, Chouaid C.

BMC Cancer. 2015 Nov 6;15:857. doi: 10.1186/s12885-015-1881-x.


Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.

Auliac JB, Fournier C, Audigier Valette C, Perol M, Bizieux A, Vinas F, Decroisette Phan van Ho C, Bota Ouchlif S, Corre R, Le Garff G, Fournel P, Baize N, Lamy R, Vergnenegre A, Arpin D, Marin B, Chouaid C, Gervais R.

Target Oncol. 2016 Apr;11(2):167-74. doi: 10.1007/s11523-015-0387-4.


Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R; Spanish Lung Cancer Group.

JAMA Oncol. 2015 May;1(2):149-57. doi: 10.1001/jamaoncol.2014.257.


ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.

Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, Viteri S, Moran T, Carcereny E, Massuti B, Vergnenegre A, de Marinis F, Molina MA, Teixido C, Rosell R.

Transl Lung Cancer Res. 2014 Jun;3(3):122-30. doi: 10.3978/j.issn.2218-6751.2014.03.02.


How old is "too old" for translational research?

Vergnenegre A, Corre R, Lena H, Le Caer H.

Transl Lung Cancer Res. 2014 Apr;3(2):116-9. doi: 10.3978/j.issn.2218-6751.2014.03.03. Review.


A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.

Barlesi F, Chouaid C, Crequit J, Le Caer H, Pujol JL, Legodec J, Vergnenegre A, Le Treut J, Fabre-Guillevin E, Loundou A, Auquier P, Simeoni MC, Thomas PA.

Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):783-90. doi: 10.1093/icvts/ivv050. Epub 2015 Mar 11.


Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.

de Marinis F, Vergnenegre A, Passaro A, Dubos-Arvis C, Carcereny E, Drozdowskyj A, Zeaiter A, Perez-Moreno P, Rosell R.

Future Oncol. 2015;11(3):421-9. doi: 10.2217/fon.14.269.


Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review.

Chouaïd C, Crequit P, Borget I, Vergnenegre A.

Clinicoecon Outcomes Res. 2014 Dec 15;7:9-15. doi: 10.2147/CEOR.S43328. eCollection 2015. Review.


Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.

Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaïd C; IFCT-GFPC investigators.

BMC Cancer. 2014 Dec 15;14:953. doi: 10.1186/1471-2407-14-953.


Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy.

Walzer S, Chouaid C, Lister J, Gultyaev D, Vergnenegre A, de Marinis F, Meng J, de Castro Carpeno J, Crott R, Kleman M, Ngoh C.

Expert Rev Anticancer Ther. 2015 Jan;15(1):121-8. doi: 10.1586/14737140.2015.961428. Epub 2014 Sep 24.


Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).

Chouaid C, Dujon C, Do P, Monnet I, Madroszyk A, Le Caer H, Auliac JB, Berard H, Thomas P, Lena H, Robinet G, Baize N, Bizieux-Thaminy A, Fraboulet G, Locher C, Le Treut J, Hominal S, Vergnenegre A.

Lung Cancer. 2014 Nov;86(2):170-3. doi: 10.1016/j.lungcan.2014.08.016. Epub 2014 Aug 29.


Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?

Chouaid C, Borget I, Vergnenegre A.

J Clin Oncol. 2014 Nov 1;32(31):3577. doi: 10.1200/JCO.2014.56.2157. Epub 2014 Sep 8. No abstract available.


Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de Las Peñas R, Karachaliou N, Sala MA, Wu Q, Isla D, Zhou Y, Baize N, Zhang F, Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez JJ, Camps C, Liu B, Rosell R; Spanish Lung Cancer Group; French Lung Cancer Group; Comprehensive Cancer Centre of Drum Tower Hospital in Nanjing.

Ann Oncol. 2014 Nov;25(11):2147-55. doi: 10.1093/annonc/mdu389. Epub 2014 Aug 27.


Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.

Auliac JB, Chouaid C, Greillier L, Monnet I, Le Caer H, Falchero L, Corre R, Descourt R, Bota S, Berard H, Schott R, Bizieux A, Fournel P, Labrunie A, Marin B, Vergnenegre A; GFPC team.

Lung Cancer. 2014 Sep;85(3):415-9. doi: 10.1016/j.lungcan.2014.07.006. Epub 2014 Jul 17. Erratum in: Lung Cancer. 2015 Feb;87(2):210. Greiller, L [corrected to Greillier, L].


Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.

Molina-Vila MA, Bertran-Alamillo J, Gascó A, Mayo-de-las-Casas C, Sánchez-Ronco M, Pujantell-Pastor L, Bonanno L, Favaretto AG, Cardona AF, Vergnenègre A, Majem M, Massuti B, Morán T, Carcereny E, Viteri S, Rosell R.

Clin Cancer Res. 2014 Sep 1;20(17):4647-59. doi: 10.1158/1078-0432.CCR-13-2391. Epub 2014 Apr 2.


The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.

Bonanno L, Costa C, Majem M, Sanchez JJ, Gimenez-Capitan A, Rodriguez I, Vergnenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R.

Oncotarget. 2013 Oct;4(10):1572-81.


Real-world healthcare resource utilization in a European non-small cell lung cancer population: the EPICLIN-Lung study.

Vergnenègre A, Carrato A, Thomas M, Jernigan C, Medina J, Cruciani G.

Curr Med Res Opin. 2014 Mar;30(3):463-70. doi: 10.1185/03007995.2013.860373. Epub 2013 Nov 18.


Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study.

Carrato A, Vergnenègre A, Thomas M, McBride K, Medina J, Cruciani G.

Curr Med Res Opin. 2014 Mar;30(3):447-61. doi: 10.1185/03007995.2013.860372. Epub 2013 Nov 18.


How many drugs in the maintenance setting for non-small-cell lung cancer? For what benefit?

Vergnenègre A.

Ann Palliat Med. 2013 Oct;2(4):170-2. doi: 10.3978/j.issn.2224-5820.2013.10.01.


Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study).

Vergnenègre A, Hominal S, Tchalla AE, Bérard H, Monnet I, Fraboulet G, Baize N, Audigier-Valette C, Robinet G, Oliviero G, Le Caer H, Thomas P, Gérinière L, Mastroianni B, Chouaïd C; GFPC 0804 team.

Lung Cancer. 2013 Nov;82(2):353-7. doi: 10.1016/j.lungcan.2013.07.014. Epub 2013 Aug 6.


Treatment of lung cancer: will financial issues become a criterion of choice?

Vergnenegre A, Borget I, Chouaid C.

Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):273-5. doi: 10.1586/erp.13.21. No abstract available.


Supplemental Content

Loading ...
Support Center